XBiotech Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Report (Form 10-Q) | 13 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 15 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly115.5MTarget: Sufficient to fund operations for at least 12 months
Quarterly Research and Development (R&D) Expense Quarterly5.2MTarget: Controlled spend aligned with clinical trial progression
Quarterly Net Loss Quarterly-5.5MTarget: Narrowing losses through optimized operational efficiency
Watch Items
- V-SPINE (PT064) Phase II Clinical Trial EnrollmentTrigger: First patient enrolled in the U.S. for active axial spondyloarthritisAction: Monitor clinical trial registry updates and company press releases for enrollment milestones.
- True Human™ Platform Licensing or Partnership AgreementsTrigger: Execution of a co-development or licensing deal with a major pharmaceutical partnerAction: Evaluate upfront cash, milestone structures, and royalty percentages to update valuation models.
- Cash Runway and Burn RateTrigger: Cash balance falling below $50 million without a partner or clinical milestoneAction: Assess potential dilutive financing risks or strategic prioritization of pipeline assets.
Research as of 19 Jun 2026